2 outstanding ASX 200 shares to buy this month according to analysts

Here are a couple of ASX 200 shares that have been rated as buys…

| More on:
a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are a lot of options for investors to choose from on the ASX 200. Two that could be in the buy zone right now are listed below.

Here's why analysts rate them as buys:

Aristocrat Leisure Limited (ASX: ALL)

The first ASX 200 share to look at is Aristocrat Leisure. It is one of the world's leading gaming technology companies responsible for many of the most popular pokie machines globally. In addition to this, the company has a growing digital business with a portfolio of hugely popular mobile games such as RAID: Shadow Legends. It is also in the process of acquiring UK listed real money gaming business Playtech for $3.9 billion.

Morgans is a fan of the company and currently has an add rating and $52.00 price target on its shares.

It commented: "We reiterate our ADD rating. In our opinion, the acquisition of PTEC gives ALL the opportunity to get to scale quickly in a market segment forecast to grow at a double-digit rate over the next five years. We expect the strong sector growth to be driven by a North America market growing at a CAGR of close to 50% as more US states liberalise and allow online iGaming and online sports betting."

CSL Limited (ASX: CSL)

Another ASX 200 share that could be in the buy zone is CSL. It is one of the world's leading biotechnology companies, comprising the CSL Behring and Seqirus businesses. Both are leaders in their respective fields – plasma therapies and vaccines.

Citi is bullish on the company, particularly following its Vifor Pharma acquisition announcement, and appears to see the weakness in the CSL share price as a buying opportunity for investors. It has a buy rating and $340.00 price target on its shares.

Citi said: "CSL has announced that the acquisition of Vifor Pharma – it is acquiring the company at CHF165.5 (US$179.25), a ~65% premium to where the stock was trading pre bid discussion and a ~37% premium to the three-month VWAP. We calculate the acquisition to be ~9% accretive to NPATA per share (NPAT before acquisition-related amortization) – a proxy for cash flow."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Blue Chip Shares

Happy man on a supermarket trolley full of groceries with a woman standing beside him.
Blue Chip Shares

Are Woolworths shares a blue-chip buy?

Would I buy this supermarket giant's shares? Here's my verdict.

Read more »

A shocked man holding some documents in the living room.
Blue Chip Shares

Why is everyone talking about the Wesfarmers share price this week?

The retail giant is in the spotlight this week.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Blue Chip Shares

3 ASX shares I would hold for the next 10 years

There's a reason why I would hold these shares for the long term.

Read more »

A group of businesspeople clapping.
Blue Chip Shares

3 ASX 200 shares for smart investors to buy and hold

Not sure where to invest? Here are three smart picks for January.

Read more »

A woman looks at a tablet device while in the aisles of a hardware style store amid stacked boxes on shelves representing Bunnings and the Wesfarmers share price
Blue Chip Shares

Wesfarmers vs Coles: Which ASX share is the best buy?

Coles offers simplicity. Wesfarmers offers diversification, capital discipline, and long-term optionality.

Read more »

Three rock climbers hang precariously off a steep cliff face, each connected to the other with the higher person holding on and the two below them connected by their arms and rope but not making contact with the cliff face.
Blue Chip Shares

3 reasons some brokers think it's time to sell CBA shares

Brokers see more losses ahead for the banking giant.

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Blue Chip Shares

A once-in-a-decade opportunity to buy CSL shares?

This biotech giant could have major upside potential in 2026.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Blue Chip Shares

Top Australian stocks to buy with $2,000 right now

Let's see why these top stocks could be great destinations for your hard-earned money.

Read more »